The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease
| Autor: | A. S. Toporkov, N. V. Topchiy |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class business.industry gastroesophageal reflux disease dexlansoprozole Reflux Proton-pump inhibitor patient adherence to therapy General Medicine Gastroenterology Internal medicine medicine Medicine Dexlansoprazole proton pump inhibitors business medicine.drug |
| Zdroj: | Медицинский совет, Vol 0, Iss 3, Pp 32-41 (2018) |
| ISSN: | 2079-701X |
| DOI: | 10.21518/2079-701x-2018-3-32-41 |
| Popis: | The flexible dosage form combined with the increased maintenance of a therapeutic dextensoprazole concentration in plasma with a modified release and prolonged inhibition of acid secretion after administration of the drug suggests that dexlansoprozole has several advantages for patients with acid-dependent diseases. The pharmacokinetic profile of dexlansoprazole is characterized by two Tmax peaks in 1–2 and 4–5 hours after administrating the drug and ensures a stable concentration of it in the blood. The efficacy of dexlansoprozole in the treatment of various forms of gastroesophageal reflux disease has been confirmed by several randomized controlled clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|